Therapeutic compositions and methods with cytokine signaling immunomodulators
A method generally includes co-administering to a subject a composition that includes an antigen and a cytokine signaling immunomodulator. The method can be for treating a subject for abuse of a drug, treating a subject for toxicity from drug abuse, treating a subject for infection by a pathogen, treating a subject for a non-communicable disease, or for increasing antibody production against the antigen. The antigen can be component of a vaccine. The cytokine-signaling immunomodulator is effective to improve the subject's immune response to the antigen compared to the subject's immune response to the antigen without the cytokine-signaling immunomodulator.
1. A method comprising:
co-administering to a subject in need of treatment for opioid drug abuse or toxicity from opioid drug exposure:
a vaccine comprising an opioid drug conjugated to a carrier polypeptide, wherein the conjugate is effective to induce production of antibody that specifically binds to the opioid drug; and
an anti-IL-4 antibody, or antigen binding fragment thereof, effective to improve the subject's immune response to the vaccine, wherein the improvement comprises an increase in antigen-specific IgG antibody in the subject, an increase in antigen-specific IgG antibody concentration in the subject, or an increase in antigen-specific IgG antibody titer in the subject compared to the subject's immune response to the vaccine without the anti-IL-4 antibody, or antigen binding fragment thereof.
2. The method of claim 1 , wherein the anti-IL-4 antibody, or antigen binding fragment thereof, is complexed with IL-4.
3. The method of claim 1 , wherein the anti-IL-4 antibody or an antigen binding fragment thereof, is a monoclonal antibody or a fragment of a monoclonal antibody.
4. A method for producing antibody against a small molecule drug, the method comprising:
administering to an animal a composition comprising:
the small molecule drug conjugated to a polypeptide carrier in an amount to induce production of antibody that specifically binds the small molecule drug; and
an anti-IL-4 antibody, or an antigen binding fragment thereof, in an amount effective to improve the animal's production of antibody against the small molecule drug antigen compared to the animal's production of antibody against the small molecule drug without the anti-IL-4 antibody or antigen binding fragment thereof.
5. The method of claim 4 , wherein the anti-IL-4 antibody, or antigen binding fragment thereof, is complexed with IL-4.
6. The method of claim 4 , wherein the anti-IL-4 antibody or an antigen binding fragment thereof, is a monoclonal antibody or a fragment of a monoclonal antibody.